
Cure
Overview
From cardiac scales to wearable sensors, these companies are bringing FDA-authorized devices into patient care. Here’s how their technology, funding, and business models stack up heading into 2027.
The real test of a remote patient monitoring device begins when it sends an alert. Who reviews it? Who intervenes? And who pays for that work? For founders building connected sensors, cardiac scales, and wearable monitors, those questions will shape the opportunity in 2027 as they work to turn FDA-authorized technology into a sustainable business.
Medicare spending on remote patient monitoring climbed 31% to $536 million in 2024, according to the U.S. Department of Health and Human Services Office of Inspector General. That growth is creating opportunities for device makers while raising questions about how healthcare providers integrate monitoring into patient care.
“The next step is moving from remote patient monitoring to remote patient management, where technology helps drive the next clinical action rather than simply generating another alert,” says Eric Bormel, managing director at investment bank Solomon Partners, where he specializes in digital health and consumer healthtech.
That transition requires clinical teams with the time and authority to respond. Andrew Schutzbank, MD, MPH, a primary care physician and healthcare adviser, warns that monitoring can generate activity without a clear plan for intervention.
“As a PCP, I can tell you most RPM alerts land in an inbox with no workflow behind them,” Schutzbank says. “No one has the staff watching dashboards or anyone empowered to intervene at 9pm.”
Reimbursement rules are also changing. Under the Centers for Medicare & Medicaid Services’ 2027 Physician Fee Schedule final rule, Medicare payment for remote physiologic and therapeutic monitoring services performed by clinical staff will require those staff to be employed by the billing practitioner or practice beginning January 1, 2029. The delay gives practices and outsourced monitoring providers more time to adapt, while making staffing and clinical integration important considerations for founders building these businesses.
The companies we've highlighted below offer different approaches to patient monitoring, from cardiac scales and glucose sensors to wearable vital-sign monitors and bedside brain monitoring. Each has at least one FDA-authorized device, and the profiles examine their funding, clinical progress, and routes to revenue. In 2027, watch how they expand adoption, pursue additional indications, and turn patient data into clinical decisions: factors that will influence whether regulatory milestones translate into lasting businesses.
Kestra Medical Technologies
Sector: Wearable cardioverter defibrillators with remote monitoring
HQ: Kirkland, WA
Year Founded:2014
Key Leaders: Brian Webster, President and CEO; Vaseem Mahboob, CFO
Number of Employees: 201-500
Stage: Public
Financial Snapshot: Raised about$202 million in an upsized IPO priced at $17 per share. For fiscal 2026, which ended April 30,revenue was $95 million, up 59%. The company initially guided to $137 million in fiscal 2027 revenue but raised its guidance to $141 million in September 2026. It ended the year with $262 million in cash and investments and signed a new $200 million term loan with Pharmakon.
Notable Investors: Bain Capital, Endeavour Vision, Andera Partners, Ally Bridge Group, Longitude Capital, Omega Funds
Key Products: The ASSURE wearable cardioverter defibrillator, which monitors heart rhythm and delivers a shock when it detects a dangerous arrhythmia, paired with a remote data platform and patient app. The FDA approved ASSURE in 2021.
Regulatory Status: FDA-approved in 2021 as a Class III device.
How It Gets Paid: Rents ASSURE to patients on a physician’s prescription and bills insurers. About 80% of fittings are now in-network, up from roughly 70% at the IPO, which raises revenue per fit.
Recent Highlights: Its ACE-PAS post-approval study has enrolled more than 21,000 patients and, per the company, showed low false alarm rates and 100% successful conversion of dangerous arrhythmias. Kestra shipped an enhanced detection algorithm to all patients in April 2026 and is collaborating with Biobeat on cuffless blood pressure monitoring for patients with hypertension.
AliveCor
Sector: Personal and 12-lead ECG devices with AI arrhythmia detection
HQ: Mountain View, CA
Year Founded: 2010
Key Leaders: Priya Abani, CEO; David E. Albert, MD, Founder and Chief Medical Officer
Number of Employees: 51-200
Stage: Private, Series F
Financial Snapshot: Closed a$65 million Series E in November 2020, followed by a Series F of undisclosed size.
Notable Investors: OMRON, Khosla Ventures, Mayo Clinic, Qualcomm Ventures, WP Global Partners, Bold Capital Partners
Key Products: KardiaMobile 6L, the credit-card-sized KardiaMobile Card and the Kardia 12L, a handheld 12-lead ECG system, all supported by the company’s Kardia AI algorithms.
Regulatory Status: FDA-cleared across the Kardia line. Kardia 12L now carries 39 cleared determinations, and KardiaMobile, KardiaMobile 6L and KardiaMobile Card can be bought without a prescription.
How It Gets Paid: Sells devices directly to consumers and through retailers, layers on KardiaCare subscriptions (noweligible for FSA and HSA spending), and sells KardiaPro and enterprise programs to physicians, payers, employers and biopharma. CMSapproved reimbursement for Kardia 12L in January 2025.
Recent Highlights: In January 2026, AliveCorreceived FDA clearance for five new detections on Kardia 12L, bringing the total to 39.
BioIntelliSense
Sector: Continuous vital-sign wearables and clinical analytics for hospital and home monitoring
HQ: Golden, CO
Year Founded: 2019
Key Leaders: David Wang, Co-Founder and CEO; James Mault, MD, Co-Founder and Executive Chairman; Henry Leung, COO; Marshal Dhillon, CTO
Number of Employees: 51-200
Stage: Private, Series B-1
Financial Snapshot: The company officially announced and closed its $45 million Series B funding round in late July 2021, led by Chimera Investment Corporation
Notable Investors: Chimera, 7wire Ventures, Pendrell, ID Ventures America, Fresenius Medical Care North America, Royal Philips, Mary Tolan, James Murren, TripleTree Holdings, UCHealth, and CU Healthcare Innovation Fund
Key Products: The BioButton wearable, which captures vital signs continuously for up to 30 days on a single-use device; a rechargeable, reusable multi-patient versioncleared by the FDA in October 2024; and the BioDashboard analytics system.
Regulatory Status: FDA-cleared in stages: the BioSticker in late 2019, the BioButton in December 2022 for adults outside critical care, and the rechargeable multi-patient BioButton with BioDashboard in October 2024.
How It Gets Paid: The company operates a provider-focused Data-as-a-Service (DaaS) model. Hospitals and healthcare organizations purchase monitoring solutions that combine devices, connectivity, software, and analytics andpay an annual subscription for devices and software; the company doesn’t sell direct to consumers. Its rural hospital pitch bundles the device with monitoring-center staffing at an estimated $10 per patient per day (company figure).
Recent Highlights: Houston Methodist becamethe first hospital to monitor all non-ICU patients with the BioButton. In 2026, the company beganpitching rural hospitals on continuous monitoring at an estimated $10 per patient per day, a figure from company materials.
Sibel Health
Sector: Wireless wearable sensors for hospital, neonatal, maternal and home monitoring
HQ: Chicago, IL
Year Founded: 2018
Key Leaders: Steve Xu, MD, Co-Founder and CEO; Jong Yoon Lee, Co-Founder and CTO; John A. Rogers, Co-Founder
Number of Employees: 51-200
Stage: Private, Series C
Financial Snapshot: Closed a$30 million Series C in March 2025 led by existing investors. In October 2025, it announced an additional Series C extension, bringing total Series C funding to $39 million.
Notable Investors: Steele Foundation for Hope, Dräger, Bill & Melinda Gates Foundation (grant), National Institutes of Health
Key Products: ANNE One, a wearable sensor platform that tracks vital signs in patients 12 and older and is also cleared for neonates and infants. ANNE Maternal is a wireless maternal-fetal monitoring system.
Regulatory Status: Seven FDA 510(k) clearances as of March 2025, covering ANNE One for patients 12 and older, neonates and infants, and the ANNE Maternal system. ANNE Maternal received its own FDA 510(k) clearance on February 26, 2026.
How It Gets Paid: Hardware sales and subscriptions to hospitals (Northwestern Medicine has purchased systems), backed by government and philanthropic funding, including the Gates Foundation and ARPA-H.
Recent Highlights: Sibel earned its seventh FDA 510(k) clearance in March 2025, one that makes ANNE One among the first devices cleared under the IEEE 11073 SDC interoperability standard. It also holds a $3.5 million ARPA-H contract to develop a wearable for continuous edema monitoring.
Bodyport
Sector: Connected cardiac scale for heart failure fluid monitoring
HQ: San Francisco, CA
Year Founded: 2015
Key Leaders: John Lipman, CEO; Corey Centen, Co-Founder, President and CTO
Number of Employees: 11-50
Stage: Private, Series A
Financial Snapshot: Raised an$11.2 million Series A in August 2020, bringing total funding to $15.8 million at the time.
Notable Investors: Boehringer Ingelheim Venture Fund, Playground Global, Initialized Capital
Key Products: The Bodyport Cardiac Scale, which looks like a bathroom scale but measures weight, pulse and peripheral impedance in about 30 seconds. Its Congestion Index algorithm and clinical dashboard flag fluid changes in patients with heart failure.
Regulatory Status: FDA 510(k) clearance in August 2022 for adults 21 and older weighing under 397 pounds.
How It Gets Paid: Sells to health systems and cardiology programs, which can bill Medicare for remote monitoring under the standard RPM codes (CPT 99453, 99454, 99457 and 99458). Bodyport operates on a B2B model and does not publicly publish standard retail pricing. While CMS initially explored consolidating these RPM codes into bundled G-codes for 2027, they opted not to finalize the consolidation, keeping the standard CPT codes active for the 2027 calendar year.
Nanowear
Sector: Cloth-based nanosensor wearables for cardiopulmonary diagnostics
HQ: Brooklyn, NY
Year Founded: 2014
Key Leaders: Venk Varadan, Co-Founder and CEO; Vijay K. Varadan, Co-Founder and Inventor
Number of Employees: 11-50
Stage: Private
Financial Snapshot: CEO Venk Varadan told Fortune in September 2024 that the company had raised about $20.5 million, largely from high-net-worth individuals and physicians rather than venture capital.
Notable Investors: Social Capital, MAS Holdings, and HeartX Accelerator
Key Products: SimpleSense, an undergarment with cloth nanosensors that captures more than 85 biomarker data points across the heart, lungs and vascular system, and SimpleSense-BP, a cuffless continuous blood pressure monitor.
Regulatory Status: Four FDA 510(k) clearances, the first in 2016 and the latest in January 2024. SimpleSense is indicated for at-home use, healthcare facilities and clinical research.
How It Gets Paid: Provides the wearable and software to health systems and research sponsors, with pilots at Maimonides Medical Center and Hackensack Meridian Health. The company hasn’t publicly detailed pricing or payer terms.
Recent Highlights: In January 2024, SimpleSense-BP became the company’sfourth FDA 510(k) clearance. In March 2025, Nanowear announced a licensing and data partnership with Dexcom to bring G7 glucose data into SimpleSense.
Biolinq
Sector: Needle-free intradermal biosensors, starting with glucose
HQ: San Diego, CA
Year Founded: 2012
Key Leaders: Richard Yang, CEO; Jared Tangney, PhD, President and CTO; Amy Vandenberg, Chief Regulatory and Clinical Officer
Number of Employees: 51-200
Stage: Private, Series C
Financial Snapshot: Raised a$100 million Series C in April 2025, following $58 million in 2024 and a $100 million Series B in 2021
Notable Investors: Alpha Wave Ventures, RiverVest Venture Partners, AXA IM Alts, LifeSci Venture Partners
Key Products: Biolinq Shine, a wearable patch with microsensors that sit just under the skin’s surface and show glucose ranges through color-coded lights, with an optional app that ties glucose patterns to activity and sleep.
Regulatory Status: De novo classification in September 2025, followed by510(k) clearance for over-the-counter sale reported in October 2026. The first indication is adults with type 2 diabetes who don’t use insulin.
How It Gets Paid: Over-the-counter sales to consumers. Pricing and payer coverage haven’t been disclosed.
Recent Highlights: The FDA granted Shinede novo classification in September 2025, making it the first needle-free continuous glucose monitor on the U.S. market. The clearance positions it as a qualitative view of glucose ranges and trends rather than a monitor for insulin dosing.
Sempulse
Sector: Wearable vital-sign monitors for tactical, emergency and remote care
HQ: San Marcos, TX
Year Founded: 2016
Key Leaders: Kurt Stump, Founder and CEO; Matt Barrera, Director of Medical Operations
Number of Employees: 2-10
Stage: Private, Series A
Financial Snapshot: Development has been supported in part by military-linked programs, including the Military Infectious Disease Research Program, the Military Operational Medicine Research Program and MTEC.
Notable Funding Sources: MassChallenge (non-equity support) and MTEC (medical technology consortium and funding/contracting channel)
Key Products: The Halo Vital Signs Monitoring System, an ear-and-neck-worn monitor that tracks pulse oximetry, pulse rate, respiratory rate, and temperature, paired with the LiveCharts app and Command Cloud.
Regulatory Status: FDA 510(k) clearance (K232495), Class II, on May 16, 2024. Halo is a prescription device for adult patients, to be used by trained healthcare providers.
How It Gets Paid: Sells to military, EMS, law enforcement, industrial and healthcare buyers, and has relied on government research awards for development. Pricing isn’t public.
Recent Highlights: Sempulse received FDA 510(k) clearance for Halo on May 16, 2024 and launched it commercially that month. In December 2024, the company reported Halo’s first credited life-saving use by EMS responders.
Alio
Sector: Non-invasive wearable remote monitoring for dialysis and end-stage kidney disease patients
HQ: Broomfield, CO
Year Founded: 2012, formerly GraftWorx
Key Leaders: Samuel Sadoulet, CEO; Mike Scobey, CTO and Chairman of the Board
Number of Employees: 11-50
Stage: Private, Series C
Financial Snapshot: Raised $18 million in the first close of its Series C in December 2022, bringing total funding to more than $50 million (the company’s figure). Third-party totals vary, from about $47 million to about $61 million. It also raised $20 million in a Series B in 2021.
Notable Investors: Widjaja Family Investment Office (led the Series C), Chase Field LLC and Thomas Krebs, former Penumbra treasurer.
Key Products: The Alio Platform: the SmartPatch wearable, worn over the vascular access site, plus a bedside hub, cloud and clinician portal. It trackspotassium, hemoglobin, hematocrit, heart rate, skin temperature and auscultation sounds. The CAVA study of up to 300 participants aims to extend monitoring to the calf, for patients without arm-based vascular access.
Regulatory Status: FDA 510(k) clearance in April 2022 for skin temperature, auscultation and heart rate in home-use settings. A second clearance in March 2023 added hematocrit, hemoglobin and potassium.
How It Gets Paid: B2B model that sells to dialysis providers, hospitals and health systems, pairing the device with recurring cloud and monitoring services. A 2021 partnership with Lifeline Vascular Care planned to offer SmartPatch on a fee-for-service basis. Pricing isn’t public.
Recent Highlights: Started a clinical trial in August 2025 testing whether the SmartPatch candetect chemotherapy side effects earlier in cancer patients. It is a 30-patient study with remote supervision byQuantify Remote Care, with an estimated completion in October 2026. In November 2024, a Clinical Kidney Journal study reported that SmartPatch hemoglobin and hematocrit readings were comparable to lab results in hemodialysis patients.
Ceribell
Sector: Point-of-care EEG with AI for seizure and delirium detection in acute care
HQ: Sunnyvale, CA
Year Founded: 2014
Key Leaders: Jane Chao, Co-Founder and CEO; Scott Blumberg, CFO
Number of Employees: 201-500
Stage: Public
Financial Snapshot: As of the November 3 Q3 report, Ceribell raised its full-year revenue guidance to $115 million to $117 million. Q3 revenue was $29.3 million, and Q3 net loss was $21.4 million. Active accounts rose to 747.
Key Products: The Ceribell System: a rapidly deployable headband and AI “Clarity” algorithms that detect seizures at the bedside. Pediatric and neonatal seizure products launched in Q2 2026. A delirium-monitoring algorithm is in a commercial pilot, with full launch expected in Q4 2026 or Q1 2027.
Regulatory Status: FDA-cleared seizure detection from pre-term neonates through adults, and a delirium monitoring 510(k) in December 2025. It also holds FDA Breakthrough Device Designation for a large vessel occlusion (LVO) stroke detection solution, which is still in development.
How It Gets Paid: Hospitals pay for the headbands and a recurring Clarity subscription. In 2025, product revenue was $67.3 million and subscription revenue was $21.7 million. CMS created a new technology add-on payment for the delirium solution, worth up to $2,171 per qualified patient, effective October 1, 2026.
Recent Highlights: Won the CMS add-on payment for delirium monitoring (effective October 1, 2026). Launched neonatal and pediatric products and started a delirium pilot in 2026. Reached 712 active hospital accounts in Q2 2026.






